Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 13/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.39 |
| ▸ | KDM1A | O60341 | 5/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418640 | 0.92 | CYP11B1 (0.39) | CYP11B1CYP11B2KDM1APDE4APDE4C | |
| SCHEMBL422755 | 0.85 | HRH4 (0.39) | — | |
| SCHEMBL417602 | 0.81 | CYP11B2 (0.39) | CYP11B1CYP11B2 | |
| SCHEMBL417644 | 0.81 | GRM2 (0.38) | CYP11B1CYP11B2 | |
| SCHEMBL421308 | 0.78 | PDE4A (0.41) | CYP11B1CYP11B2KDM1APDE4APDE4C | |
| SCHEMBL420999 | 0.78 | NPC1 (0.36) | CYP11B1CYP11B2 | |
| SCHEMBL420667 | 0.77 | MEN1 (0.36) | — | |
| SCHEMBL419641 | 0.77 | HRH4 (0.37) | — | |
| SCHEMBL422621 | 0.75 | PIK3CA (0.38) | — | |
| SCHEMBL420411 | 0.75 | RAB9A (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404670-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| US-8063032-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100204214-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204214-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | CYP11B1 3789/4885CYP11B2 3139/4885KDM1A 705/4885 |
| US-20120022050-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | CYP11B1 3789/4885CYP11B2 3139/4885KDM1A 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.